Y-mAbs Therapeutics Inc (YMAB)
10.10
-0.44
(-4.17%)
USD |
NASDAQ |
Nov 21, 16:00
9.95
-0.15
(-1.49%)
Pre-Market: 08:26
Y-mAbs Therapeutics Profit Margin (Quarterly): -37.91% for Sept. 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -37.91% |
| June 30, 2024 | -40.57% |
| March 31, 2024 | -33.26% |
| December 31, 2023 | -4.23% |
| September 30, 2023 | -37.88% |
| June 30, 2023 | -30.37% |
| March 31, 2023 | -31.55% |
| December 31, 2022 | 3.68% |
| Date | Value |
|---|---|
| September 30, 2022 | -219.6% |
| June 30, 2022 | -380.9% |
| March 31, 2022 | -267.7% |
| December 31, 2021 | -384.4% |
| September 30, 2021 | -321.9% |
| June 30, 2021 | -209.5% |
| March 31, 2021 | |
| December 31, 2020 | -96.06% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-384.4%
Minimum
Dec 2021
3.68%
Maximum
Dec 2022
-139.5%
Average
-40.57%
Median
Jun 2024
Profit Margin (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | -49.65% |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
| Oragenics Inc | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -24.45% |
| Return on Assets | -18.50% |
| Return on Invested Capital | -24.45% |
| Gross Profit Margin (Quarterly) | 87.82% |
| Operating Margin (Quarterly) | -46.41% |
| Return on Net Operating Assets | -66.74% |